+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Urinary Tract Cancer Market: By Type; By Diagnostic Tools; By Treatment & By Region - Forecast 2016-2022

  • ID: 4033455
  • Report
  • 165 pages
  • IndustryARC
1 of 2
Urinary tract cancer was the ninth most frequently occurring cancer type with a high reoccurrence rate in, according to The World Health Organization. The early symptoms of urinary tract cancer is the presence of blood in the urine, haematuria and the risk of this type of cancer is high among the smokers, those with urinary tract infections, geriatric population, and workers in chemical industries. Globally, development of efficient and advanced medicine and diagnostic tools, rise in the awareness among people regarding diseases, increasing government initiatives and rigorous research activities across the globe, growing number of smokers around the world, and rise in prevalence of a sedentary lifestyle are the prime growth drivers of the urinary tract cancer market. In addition, increase in diagnosis and adoption of urinary tract cancer treatments in emerging economies such as China, India and others, will create new opportunities for the urinary tract cancer market. However, higher cost of research and development is the key restraint for the urinary tract cancer market.

Geographically, North America dominated the urinary tract cancer market, because of high medical reimbursement facilities, higher medical expenditure, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing aging population, rise in consumer awareness, increasing incidences of urinary tract infections, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the types of urinary tract cancer, urothelial carcinoma has the highest market share in the urinary tract cancer market due to a higher occurrence rate of approximately 90%.

This report identifies the urinary tract cancer market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the urinary tract cancer market.

This report segments the urinary tract cancer market on the basis of type, diagnostic tools, treatment, and regional market as follows:
Urinary Tract Cancer Market, By Type: Squamous Cell Carcinoma, Transitional Cell Carcinoma, Adenocarcinoma, and Others
Urinary Tract Cancer Market, By Diagnostic Tools: Biopsy, Cystoscopy, Urine Cytology, Imaging Test
The report has focused study on urinary tract cancer market by basis of treatment such as: Biological Therapy, Surgical Treatment, Radiation Therapy, Chemotherapy, and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the urinary tract cancer market. Some of the major companies’ profiles in detail are as follows:
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.

Kyowa Hakko Kirin Co., Ltd.

Boehringer Ingelheim GmbH
Eli Lilly and Company
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Urinary Tract Cancer Market – Overview

2. Executive Summary

3. Urinary Tract Cancer Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Urinary Tract Cancer Market– Forces
4.1. Drivers
4.1.1. Development of efficient and advance medicine and diagnostic tools
4.1.2. Growing prevalence of a sedentary lifestyle
4.2. Restraints
4.2.1. Higher cost of research and development
4.3. Opportunities
4.3.1. Emerging economies
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Urinary Tract Cancer Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Urinary Tract Cancer Market, By Type
6.1. Squamous Cell Carcinoma
6.2. Transitional Cell Carcinoma
6.3. Adenocarcinoma
6.4. Others

7. Urinary Tract Cancer Market, By Diagnostic Tests
7.1. Biopsy
7.2. Cystoscopy
7.3. Urine Cytology
7.4. Imaging Test
7.5. Others

8. Urinary Tract Cancer Market, By Treatment
8.1. Biological Therapy
8.2. Surgical Treatment
8.3. Radiation Therapy
8.4. Chemotherapy
8.5. Others

9. Urinary Tract Cancer Market, By Geography
9.1. Europe
9.1.1. Germany
9.1.2. France
9.1.3. Italy
9.1.4. Spain
9.1.5. Russia
9.1.6. U.K.
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.1. China
9.2.2. India
9.2.3. Japan
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.3.1. U.S.
9.3.2. Canada
9.3.3. Mexico
9.4. Rest of the World (RoW)
9.4.1. Brazil
9.4.2. Rest of RoW

10. Urinary Tract Cancer – Entropy
10.1. Expansion
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract

11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. Bristol-Myers Squibb Company
11.2. F. Hoffmann-La Roche Ltd.
11.3. Kyowa Hakko Kirin Co., Ltd.
11.4. Boehringer Ingelheim GmbH
11.5. Eli Lilly and Company
11.6. Novartis AG
11.7. IkerChem S.L.
11.8. GlaxoSmithKline plc
11.9. Genzyme Corporation
11.10. Medical Enzymes AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 2